Esprit Pharma has successfully completed a Series B funding round, raising $90,790,000 in financing from a group of leading venture capital and private equity investors.

Firms participating in the Series B round included existing investors New Enterprise Associates (NEA), Apax Partners, Inc., Domain Associates LLC and Montagu Newhall Global Partners plus new investors Oak Investment Partners and clients advised by Performance Equity Management.

INFO SOURCES

Esprit Pharma

FIRMS

Esprit Pharma is a privately held, niche-oriented pharmaceutical company located in East Brunswick, NJ, committed to improving patient outcomes and well-being within the urology and women's healthcare fields. Esprit focuses on serving the unique needs of physicians by identifying and selectively acquiring and maximizing the potential of approved and late-stage development medicines for these specialty markets and providing support through internal expertise and a dedication to medical education.

ADVISORS

Finn Dixon & Herling LLP represented Oak Investment Partners and Jenner & Block represented Performance Equity. The New York law firm Milbank Tweed represented Esprit Pharma in the deal.

Reed Smith LLP represented the investors NEA, APAX, Domain and Montagu Newhall who accounted for $58.5 million of the round.